Articles tagged ‘Dronaderone’

“Worldwide, strokes are the most common cause of death. This makes it a top priority for medicine to expand prevention in this area,” said Prof. Dr. Karl Max Einhäupl, from the University Clinic Charité in Berlin, who is co-chair of the Annual Meeting of the European Neurological Society (ENS) which took place in Berlin recently.

The National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)1 for Multaq® (dronedarone) indicating its intention to recommend its use for the management of patients with atrial fibrillation (AF).

It has recently been announced that the U.S. Food and Drug Administration (FDA) has approved the use of dronaderone (Multaq®) for patients with atrial fibrillation (AF) or atrial flutter (AFL). Multaq® is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.